共 50 条
- [31] BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALSGASTROENTEROLOGY, 2023, 164 (06) : S213 - S213Rubin, David T.Hindryckx, PieterHibi, ToshifumiMcGinnis, KimGibble, Theresa H.Keohane, AnthonyRegueiro, Miguel D.
- [32] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDYGASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394Dubinsky, Marla C.Irving, Peter M.Li, XingyuanHowaldt, StefaniePokrotnieks, JurisKrueger, Kathryn A.Laskowski, JanelleLissoos, TrevorMilata, JoeMorris, NathanArora, VipinMilch, CatherineSands, Bruce E.
- [33] Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 studyJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 133 - 133Begun, J.Dubinsky, M. C.Irving, P. M.Li, X.Howaldt, S.Pokrotnieks, J.Krueger, K.Laskowski, J.Lissoos, T.Milata, J.Morris, N.Arora, V.Milch, C.Sands, B. E.
- [34] Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trialsJOURNAL OF CROHNS & COLITIS, 2023, 17 : 646 - 646Friedrich, S.Chua, L.Zhang, X. C.
- [35] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM RANDOMISED PHASE 2 AND PHASE 3 INDUCTION AND MAINTENANCE TRIALSGASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1218Friedrich, StuartChua, LaiyiZhang, Xin
- [36] Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis From Two Phase 3 Trials and an Open-Label Extension StudyMULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 56 - 57Selmaj, K. W.Cohen, J. A.Steinman, L.Comi, G.Bar-Or, A.Hartung, H.Montalban, X.Kappos, L.Sheffield, J. K.Krakovich, A.Cheng, C.Riolo, J.Silva, D.Cree, B. A.
- [37] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND StudyJOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12Louis, E.Panaccione, R.Parkes, G.Peyrin-Biroulet, L.Ferrante, M.Hisamatsu, T.Siegmund, B.Kalabic, J.Levine, P.Neimark, E.Wallace, K.Chen, S.Cheng, L.Duan, W. R.Armuzzi, A.Biederman, L.Loftus, E.Melmed, G.Schreiber, S.
- [38] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S624 - S625Louis, EdouardPanaccione, RemoParkes, GarethPeyrin-Biroulet, LaurentFerrante, MarcTakeuchi, KenSiegmund, BrittaLevine, PhillipKalabic, JasminaNeimark, EzequielWallace, KoriChen, SuDuan, W. RachelArmuzzi, AlessandroBiedermann, LucLoftus, Edward V.Melmed, GilSchreiber, Stefan
- [39] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S3 - S3Louis, EdouardPanaccione, RemoParkes, GarethPevrin-Biroulet, LaurentFerrante, MarcTakeuchi, KenSiegmund, BrittaLevine, PhillipKalabic, JasminaNeimark, EzequielWallace, KoriChen, SuDuan, W. RachelArmuzzi, AlessandroBiedermann, LucLoftus, EdwardMelmed, GilSchreiber, Stefan
- [40] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitisJOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60Sandborn, W. J.Sands, B.Kobayashi, T.Tuttle, J.Schmitz, J.Durante, M.Higgs, R.Canavan, J. B.Siegel, R.Ferrante, M.